Literature DB >> 2212595

Animal models of osteomyelitis. Knowledge, hypothesis, and speculation.

J P Rissing1.   

Abstract

Each animal model has provided insights. Particularly important was the considerable resistance of bone to infection without manipulation (no morrhuate, fracture, rod, wax, or prosthesis). Such perturbations allow bone infection with much smaller inocula. Typical inocula decreases are 1000 to 10,000 fold. Staphylococci may have a selective advantage in bone because of specialized or tropic binding, perhaps to cartilage or collagen. Osteoclast-induced resorption of hydroxyapatite might explain the distribution of some osteomyelitis. Increased osteoclast activity could link the susceptible metaphyseal regions, the repetitively traumatized diabetic foot, a history of blunt bone trauma, fracture, and perhaps even nearby soft tissue infection. Diagnosis remains difficult; gallium-67 and indium111 labeled WBC probably deserve additional investigation. Therapeutic failures in the rabbit and rat models mirror clinical experience. Clindamycin, rifampin, and quinolones are promising. Neither systemic nor local antimicrobial prophylaxis is well studied yet.

Entities:  

Mesh:

Year:  1990        PMID: 2212595

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  11 in total

1.  [Animal models of osteomyelitis].

Authors:  T Kälicke; U Schlegel; C Kraft; C Wingenfeld; G Muhr; S Arens
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

2.  Bone and joint infections.

Authors:  T Louie
Journal:  Can J Infect Dis       Date:  1992-03

3.  (68)Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones.

Authors:  Petteri Lankinen; Tatu J Mäkinen; Tiina A Pöyhönen; Pauliina Virsu; Satu Salomäki; Antti J Hakanen; Sirpa Jalkanen; Hannu T Aro; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-24       Impact factor: 9.236

4.  Periodontal bacteria in rabbit mandibular and maxillary abscesses.

Authors:  Kerin L Tyrrell; Diane M Citron; Jeffrey R Jenkins; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus.

Authors:  Tatu J Mäkinen; Petteri Lankinen; Tiina Pöyhönen; Jari Jalava; Hannu T Aro; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-09       Impact factor: 9.236

6.  Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.

Authors:  Jyri K Koort; Tatu J Mäkinen; Esa Suokas; Minna Veiranto; Jari Jalava; Juhani Knuuti; Pertti Törmälä; Hannu T Aro
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Establishment of a real-time, quantitative, and reproducible mouse model of Staphylococcus osteomyelitis using bioluminescence imaging.

Authors:  Haruki Funao; Ken Ishii; Shigenori Nagai; Aya Sasaki; Tomoyuki Hoshikawa; Mamoru Aizawa; Yasunori Okada; Kazuhiro Chiba; Shigeo Koyasu; Yoshiaki Toyama; Morio Matsumoto
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

Review 8.  Implantable antimicrobial biomaterials for local drug delivery in bone infection models.

Authors:  Jeremy D Caplin; Andrés J García
Journal:  Acta Biomater       Date:  2019-01-14       Impact factor: 8.947

9.  Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; H Lagler; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

10.  Animal models for the study of osteomyelitis.

Authors:  Mitul Patel; Yuri Rojavin; Amir A Jamali; Samantha J Wasielewski; Christopher J Salgado
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.